---
title: "Corcept Therapeutics Incorporated (CORT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CORT.US.md"
symbol: "CORT.US"
name: "Corcept Therapeutics Incorporated"
industry: "Pharmaceuticals"
datetime: "2026-05-19T21:36:09.183Z"
locales:
  - [en](https://longbridge.com/en/quote/CORT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CORT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CORT.US.md)
---

# Corcept Therapeutics Incorporated (CORT.US)

## Company Overview

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.corcept.com](https://www.corcept.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: B (0.29)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 13 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 12.20% |  |
| Net Profit YoY | -64.77% |  |
| P/B Ratio | 9.28 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5917500532.32 |  |
| Revenue | 769096000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.07% | C |
| Profit Margin | 6.16% | B |
| Gross Margin | 98.25% | A |
| Revenue YoY | 12.20% | B |
| Net Profit YoY | -64.77% | E |
| Total Assets YoY | -3.73% | D |
| Net Assets YoY | -6.63% | D |
| Cash Flow Margin | 258.04% | A |
| OCF YoY | 12.20% | B |
| Turnover | 0.93 | A |
| Gearing Ratio | 21.71% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Corcept Therapeutics Incorporated",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "12.20%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.77%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "9.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5917500532.32",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "769096000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.07%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "6.16%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "98.25%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "12.20%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-64.77%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-3.73%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.63%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "258.04%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "12.20%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.93",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "21.71%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 126.76 | 54/190 | 72.09 | 57.01 | 41.04 |
| PB | 9.28 | 178/190 | 12.57 | 11.20 | 6.68 |
| PS (TTM) | 7.69 | 110/190 | 11.39 | 10.54 | 5.70 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 1 | 17% |
| Hold | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 58.22 |
| Highest Target | 110.00 |
| Lowest Target | 44.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CORT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CORT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CORT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CORT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**